Advertisement

/FROM PR NEWSWIRE DALLAS 888-776-3971/

STK NASDAQ-NMS:ARNA

IN HEA MTC PHA

SU TDS CCA

TO BUSINESS, HEALTH, AND MEDICAL EDITORS:

Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences

SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc.

(NASDAQ: ARNA) announcedtoday that Jack Lief, Arena's President and

Chief Executive Officer, and Dominic P. Behan, Ph.D., Arena's Senior

Vice President and Chief Scientific Officer, are scheduled to present

a corporate overview and update at two upcoming investor conferences

at the WaldorfAstoria in New York City.

-- 14th Annual BIO CEO & Investor Conference Presentation: Tuesday,

February 14, 2012, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time)

-- Leerink Swann 2012 Global Healthcare Conference Presentation:

Wednesday, February 15, 2012, at 2:00 p.m. Eastern Time (11:00 a.m.

Pacific Time)

A live audio webcast of each presentation will be available under the

investor relations section of Arena's website at www.arenapharm.com. A

replay of each presentation will be available for 30 days following

the event. Please connect to Arena's website several minutes prior to

the start of the webcast to ensure adequate time for any software

download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on

discovering, developing and commercializing oral drugs that target G

protein-coupled receptors, an important class of validated drug

targets, in four major therapeutic areas: cardiovascular, central

nervous system, inflammatory and metabolic diseases. Arena is seeking

marketing approval of its most advanced drug candidate, which is

intended for weight management and has been assigned by the US Food

and Drug Administration (FDA) a new Prescription Drug User Fee Act

(PDUFA) target date of June 27, 2012.

Arena Pharmaceuticals@ and Arena@ are registered service marks of the

company.

Forward-Looking Statements

Certain statements in this press release are forward-looking

statements that involve a number of risks and uncertainties. Such

forward-looking statements include statements about the therapeutic

indication of Arena's most advanced drug candidate, lorcaserin;

seeking marketing approval of lorcaserin; the FDA's review of the

resubmitted lorcaserin NDA and the potential timing for the FDA to

complete such review; and Arena's focus, goals, strategy, research and

development programs, and ability to develop compounds and

commercialize drugs. For such statements, Arena claims the protection

of the Private Securities Litigation Reform Act of 1995. Actual events

or results may differ materially from Arena's expectations. Factors

that could cause actual results to differ materially from the

forward-looking statements include, but are not limited to, the

following: the timing of regulatory review and approval is uncertain,

and the FDA may not complete its review of the resubmitted lorcaserin

NDA by the PDUFA date; the FDA advisory committee meeting for

lorcaserin may not be held as expected; nonclinical and clinical data

is voluminous and detailed, and regulatory agencies may interpret or

weigh the importance of data differently and reach different

conclusions than Arena or others, request additional information, have

additional recommendations or change their guidance or requirements

before or after approval; data and other information related to

lorcaserin and Arena's other research and development programs may not

meet safety or efficacy requirements or otherwise be sufficient for

regulatory review or approval; Arena's submission of a marketing

authorization application for regulatory approval of lorcaserin may

not be submitted when anticipated, if at all; unexpected or

unfavorable new data; risks related to commercializing new products;

Arena's ability to obtain and defend its patents; the timing, success

and cost of Arena's research and development programs; results of

clinical trials and other studies are subject to different

interpretations and may not be predictive of future results; clinical

trials and other studies may not proceed at the time or in the manner

expected or at all; having adequate funds; risks related to relying on

collaborative agreements; the timing and receipt of payments and fees,

if any, from collaborators; and satisfactory resolution of pending and

any future litigation or other disagreements with others. Additional

factors that could cause actual results to differ materially from

those stated or implied by Arena's forward-looking statements are

disclosed in Arena's filings with the Securities and Exchange

Commission. These forward-looking statements represent Arena's

judgment as of the time of this release. Arena disclaims any intent or

obligation to update these forward-looking statements, other than as

may be required under applicable law.

Arena Pharmaceuticals, Inc.

Robert E. Hoffman, Vice President, Finance and Chief Financial Officer

858.453.7200

Investor Contact: Russo Partners, LLC Media Contact: Russo Partners, LLC

Cindy McGee, Vice President David Schull, President

cindy.mcgee@russopartnersllc.com david.schull@russopartnersllc.com

619.213.6995 858.717.2310

SOURCE Arena Pharmaceuticals, Inc.

-0- 02/08/2012

/Web Site: http://www.arenapharm.com

(NASDAQ-NMS:ARNA) /

CO: Arena Pharmaceuticals, Inc.

ST: California

IN: HEA MTC PHA

SU: TDS CCA

PRN

-- LA49603 --

0000 02/08/2012 13:00:00 EDT http://www.prnewswire.com

Advertisement
Advertisement